To analyze the risk with much greater power, we therefore analyzed meningioma risks in the Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) study, a large cross-European cohort study of patients treated with r-hGH since 1984. Here, GH1 is linked to meningioma.